Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: Getting to goalMCKENNEY, James M.Pharmacotherapy. 2003, Vol 23, Num 9, pp 26-33, issn 0277-0008, 8 p., 2Article

Potential nontraditional applications of statinsMCKENNEY, James M.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1063-1071, issn 1060-0280, 9 p.Article

Achieving blood lipid goals in patients with coronary artery diseaseMCKENNEY, James M.American journal of health-system pharmacy. 2001, Vol 58, Num 5, pp 415-419, issn 1079-2082Article

Getting to goal: the pharmacist's role in managing dyslipidemiaMCKENNEY, James M.Pharmacotherapy. 2003, Vol 23, Num 9, issn 0277-0008, 31 p., 2Serial Issue

Pharmacotherapy of dyslipidemiaMCKENNEY, James M.Cardiovascular drugs and therapy. 2001, Vol 15, Num 5, pp 413-422, issn 0920-3206Article

New cholesterol guidelines, new treatment challengesMCKENNEY, James M.Pharmacotherapy. 2002, Vol 22, Num 7, pp 853-863, issn 0277-0008Article

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemiaMCKENNEY, James M; SICA, Domenic.Pharmacotherapy. 2007, Vol 27, Num 5, pp 715-728, issn 0277-0008, 14 p.Article

Report of the National Lipid Association's Safety Task Force: The NonstatinsMCKENNEY, James M.The American journal of cardiology. 2007, Vol 99, Num 6A, issn 0002-9149, 65 p., SUPSerial Issue

Pharmacologic characteristics of statinsMCKENNEY, James M.Clinical cardiology. Supplement (Mahwah, NJ). 2003, Vol 26, Num 3, pp III.32-III.38Conference Paper

Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering : Benefits versus risksMCKENNEY, James M.The American journal of cardiology. 2005, Vol 96, Num 4, pp 60E-66E, issn 0002-9149, SUPConference Paper

What's new in lipid management?THOMPSON, Paul D.Pharmacotherapy. 2003, Vol 23, Num 9, pp 34-40, issn 0277-0008, 7 p., 2Article

Role of the pharmacist in establishing lipid intervention programsITO, Matthew K.Pharmacotherapy. 2003, Vol 23, Num 9, pp 41-47, issn 0277-0008, 7 p., 2Article

Safety considerations with fibrate therapy. CommentaryDAVIDSON, Michael H; ARMANI, Annemarie; MCKENNEY, James M et al.The American journal of cardiology. 2007, Vol 99, Num 6A, issn 0002-9149, 3C-21C, SUPArticle

Safety considerations with gastrointestinally active lipid-lowering drugs. CommentaryJACOBSON, Terry A; ARMANI, Annemarie; MCKENNEY, James M et al.The American journal of cardiology. 2007, Vol 99, Num 6A, issn 0002-9149, 47C-58C, SUPArticle

Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goalsSHEPHERD, James; HUNNINGHAKE, Donald B; BARTER, Philip et al.Atherosclerosis. Supplement (Amsterdam). 2004, Vol 5, Num 3, pp 115-123, issn 1567-5688, 9 p.Article

Safety considerations with omega-3 fatty acid therapyBAYS, Harold E; HARRIS, William S.The American journal of cardiology. 2007, Vol 99, Num 6A, issn 0002-9149, 35C-46C, SUPArticle

Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterolBAYS, Harold E; MCKENNEY, James M; DUJOVNE, Carlos A et al.The American journal of cardiology. 2003, Vol 92, Num 5, pp 538-543, issn 0002-9149, 6 p.Article

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemiaMCKENNEY, James M; MCCORMICK, Lisa S; SCHAEFER, Ernst J et al.The American journal of cardiology. 2001, Vol 88, Num 3, pp 270-274, issn 0002-9149Article

Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemiaCHEN, Fabian; MACCUBBIN, Darbie; LIZHEN YAN et al.International journal of cardiology. 2013, Vol 167, Num 1, pp 225-231, issn 0167-5273, 7 p.Article

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)MCKENNEY, James M; JONES, Peter H; BAYS, Harold E et al.Atherosclerosis. 2007, Vol 192, Num 2, pp 432-437, issn 0021-9150, 6 p.Article

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levelsDAVIDSON, Michael H; MCKENNEY, James M; SHEAR, Charles L et al.Journal of the American College of Cardiology. 2006, Vol 48, Num 9, pp 1774-1781, issn 0735-1097, 8 p.Article

Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemiaDANSKY, Hayes M; BLOOMFIELD, Daniel; GIBBONS, Patrice et al.The American heart journal. 2011, Vol 162, Num 4, pp 708-716, issn 0002-8703, 9 p.Article

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)JONES, Peter H; DAVIDSON, Michael H; STEIN, Evan A et al.The American journal of cardiology. 2003, Vol 92, Num 2, pp 152-160, issn 0002-9149, 9 p.Article

Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. DiscussionsSHEPHERD, James; HUNNINGHAKE, Donald B; BARTER, Philip et al.The American journal of cardiology. 2003, Vol 91, Num 5A, pp 11C-19C, issn 0002-9149Conference Paper

Atorvastatin with or without an Antibody to PCSK9 in Primary HypercholesterolemiaROTH, Eli M; MCKENNEY, James M; HANOTIN, Corinne et al.The New England journal of medicine. 2012, Vol 367, Num 20, pp 1891-1900, issn 0028-4793, 10 p.Article